Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York, NY. 

Steve Lundy, President and CEO of Venaxis™, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:Piper Jaffray 25th Annual Healthcare ConferenceDate:Tuesday, December 3, 2013 Time:9:30 am (Eastern Time) Location: 

The New York Palace Hotel, New York, NY The presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast will be archived and available for 90 days.

Separately, Venaxis is scheduled to ring The NASDAQ Stock Market Closing Bell on December 6, 2013 in a ceremony to celebrate the company's recent achievements as it advances the APPY1 Test toward potential FDA clearance and expands its commercial footprint in the EU.  Venaxis remains on track to complete patient enrollment for its pivotal clinical study of the APPY1 Test in the United States at or around the end of 2013.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicit
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- InferMed , s ... will augment ... olutions suite   Elsevier , a ... services, announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ... therapeutics that address unmet medical needs in women,s ... will present at the Cantor Fitzgerald Inaugural ... 2015Time: , 4:45 PM EDTLocation: , Le Parker ... , www.juniperpharma.com, under  ,Investor, or  click ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., ... a clinical trial to evaluate the safety, tolerability, pharmacokinetics, ... Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide ... autoimmune diseases. , , The Phase ...
... CITY, Aug. 25 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: ... effective and affordable vaccines based on proprietary manufacturing ... it has received clearance from Health Canada to ... its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrollment ...
... , SAN MATEO, Calif., Aug. 25 ... on developing and commercializing novel pain management therapies, today announced the ... a director and Audit Committee chairman, effective August 20, 2009. Mr. ... company focused on exploiting a novel, Nobel Prize winning method of ...
Cached Biology Technology:Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/16/2015)... Fingerprint Cards has received an order of 375 ... from one of its module partners in Asia ... the third quarter 2015. The sensors will be used by ... Jörgen Lantto, CEO of FPC, comments: " This order   ... smartphone OEMs in integrating touch fingerprint sensors in   their ...
(Date:6/15/2015)... , June 15, 2015 A new ... Telstra reveals the majority of US consumers using mobile banking ... biometrics, such as fingerprint and voiceprint, instead of having to ... According to Telstra,s " Mobile Identity   -   The ... report, with smartphones now the primary channel used by Gen ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... Michigan State University researchers looking at the effects of ... calorie-restricted diet were more likely to die after being ... While research suggests inflammation associated with obesity ... the study results revealed a low-calorie diet may actually ...
... on the BP Deepwater Horizon drilling rig in the Gulf ... to understand the impact that this disaster has had on ... at a rate of approximately 53,000 barrels per day before ... study confirms that oil from the Macondo well made it ...
... is now open for the forthcoming International Polar Year ... 22-27 April 2012, Montral, Canada The IPY 2012 ... the largest and most important scientific conferences for polar ... thought-provoking panel discussions and workshops will provide the focal ...
Cached Biology News:Low-calorie diet may be harmful for bowel disease patients 2Study confirms oil from Deepwater Horizon disaster entered food chain in the Gulf of Mexico 2International Polar Year conference: From knowledge to action 2
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: